← All trials
NCT05324059
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Jun 30, 2022
- Completion date
- Jul 31, 2022
- First posted
- Apr 12, 2022
- Last posted
- Apr 20, 2022
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- CICMEX Centro de Investigación Clínica de MéxicoOverall official - principal investigator
- Instituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo y Enfermedades MetabolicasOverall official - principal investigator
- CICMEX Centro de Investigación Clínica de MéxicoOfficial
- Imacen S.A. de C.V.Official
- Instituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo y Enfermedades MetabolicasOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.